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Central obesity and dietary
intake in HIV/AIDS patients
Obesidade abdominal e consumo
alimentar em portadores de HIV/
Aids
ABSTRACT
OBJECTIVE: To assess the association between dietary intake and central obesity
among people living with HIV/AIDS and receiving highly active antiretroviral therapy.
METHODS: A cross-sectional study was conducted involving 223 adult individuals
in the city of São Paulo city in 2002. The study population was classified according
to central obesity, defined as waist-to-hip ratio >0.95 for men and >0.85 for women.
The dietary variables studied were energy consumption (in calories and calories/kilo
of body weight), macronutrients (in grams and % of energy intake), total fiber
(grams) and fruit and vegetables intake (grams). The potential confounders examined
were sex, skin color, age, schooling, income, body mass index, physical activity,
smoking habits, peripheral CD4+ T lymphocyte count and length of protease inhibitor
use. The multiple logistic regression model was performed in order to evaluate the
association between central obesity and dietary intake.
RESULTS: The prevalence of central obesity was 45.7% and it was associated with
greater consumption of lipids: for every increase of 10g of lipid intake the odds of
central obesity increased 1.28 times. Carbohydrate consumption showed negative
association (OR=0.93) with central obesity after adjustment for control variables.
CONCLUSIONS: The results suggest that the amount of carbohydrates and lipids
in the diet, regardless of total energy intake, may modify the chance of developing
central obesity in the studied population. Nutritional interventions may be beneficial
for preventing central obesity among HIV/AIDS patients.
KEYWORDS: Obesity. HIV-associated lipodystrophy syndrome. Anti-HIV
agents, adverse effects. Food consumption. Dietary fats. Waist-hip ratio.
Cross-sectional studies.
RESUMO
OBJETIVO: Avaliar a associação entre consumo alimentar e presença de obesidade
abdominal em indivíduos infectados pelo HIV/Aids, em uso de terapia antiretroviral
de alta potência.
MÉTODOS: Trata-se de estudo transversal envolvendo 223 indivíduos adultos,
realizado no município de São Paulo, em 2002. A população de estudo foi classificada
de acordo com a obesidade abdominal, definida pela razão das circunferências da
cintura e quadril >0,95 para os homens e >0,85 para mulheres. As variáveis dietéticas
estudadas foram consumo de energia (calorias e calorias/quilo de peso corporal),
macronutrientes (em gramas e % da energia ingerida), fibra total (gramas) e consumo
de frutas, verduras e legumes (gramas). Potenciais fatores de confusão examinados
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foram sexo, raça, idade, escolaridade, renda, índice de massa corporal, nível de atividade
física, tabagismo, contagem de linfócitos T CD4+ e tempo de uso de inibidor de
protease. Estimou-se modelo de regressão logística para avaliar a relação entre obesidade
abdominal e consumo alimentar.
RESULTADOS: A prevalência de obesidade abdominal foi de 45,7% e esteve
associada ao maior consumo de lipídeos: para cada aumento de 10 g de lipídio na
dieta a chance aumentou 1,28 vezes. O consumo de carboidratos mostrou-se
negativamente associado (OR=0,93) com a presença de obesidade abdominal após
ajuste pelas variáveis de controle.
CONCLUSÕES: Os resultados sugerem que a quantidade de carboidratos e lipídeos
na dieta, independente do consumo energético, pode modificar a chance de desenvolver
obesidade abdominal na população estudada. Intervenções nutricionais podem ser
benéficas na prevenção de obesidade abdominal entre pacientes vivendo com HIV/Aids.
DESCRITORES: Obesidade. Síndrome de lipodistrofia associada ao HIV.
Agentes anti-retrovirais, efeitos adversos. Consumo de alimentos. Lipídeos
na dieta. Relação cintura-quadril. Estudos transversais.
INTRODUCTION
There has been great progress in the treatment of HIV/
AIDS infection using medications, especially the use
of highly active antiretroviral therapy (HAART) has
ensured a significant increase in the survival of HIV-
infected individuals in different regions around the
world.3,19 The policy of universal free distribution of
antiretroviral medications implemented in Brazil has
ensured a notable increase in survival parallel to a
reduction in the incidence of opportunistic infections
and, consequently, a reduction in the rate of hospi-
talization among Brazilians living with HIV/AIDS.13
On the other hand, adverse events associated with
therapy have been described among people living
with HIV/AIDS and receiving highly active antiret-
roviral therapy, thereby placing new demands on the
services providing integrated care for these patients.
In this scenario, central obesity is a frequently mor-
phological abnormality seen among both HIV-posi-
tive men and women.6
Central obesity is described as the presence of excess
fat in the abdomen, out of proportion to total body fat,
having three compartments: visceral, retroperitoneal,
and subcutaneous.15 In healthy populations, it has now
been showed that the deposition of abdominal fat is
related to dietary intake, and it is an independent pre-
dictor of risk factors and morbidity.22 Waist-to-hip ra-
tio has been used in a number of epidemiologic stud-
ies to show increased risk for diabetes, coronary artery
disease, and hypertension. Nonetheless, waist circum-
ference is the most practical anthropometric measure-
ment for assessing abdominal fat.15, 21
The present study focused on dietary components that
had been identified in previous studies as determi-
nants of metabolic syndromes and had been associ-
ated to the development of central obesity.9,11,22 The
objective was to investigate the potential association
of dietary components to the development of central
obesity in people living with HIV/AIDS and receiving
HAART. Therefore, there were examined the differences
in dietary intake between individuals with and with-
out abdominal fat deposition and the relationship be-
tween dietary components and central obesity.
METHODS
A cross-sectional study was conducted comprising
individuals of both sexes aged between 20 and 59
years who had HIV/AIDS and had been using HAART
with protease inhibitors for at least three years. They
were being followed up at a reference service for the
treatment of HIV/AIDS patients in the city of São
Paulo, southeastern Brazil. This clinic is located in
the central region of the city and accounts for outpa-
tient follow-up of around 4,000 adult patients.
Recruitment for the study was carried out between
March and June 2002 on the basis of consecutive
sampling in accordance with patients’ order of ar-
rival for their periodic consultation with the clinic’s
infectious disease doctor. Patients were excluded from
the study if they were undergoing treatment with
corticoids, anabolic steroids or growth hormone; if
they had had active opportunistic diseases (infections
or tumors) in the three months prior to recruitment; or
if they had gone through surgery such as liposuction
or liposculpture during the six months prior to the
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study. Pregnant women or using oral contraceptives
were also excluded. Out of 276 patients invited to
participate in the study, 27 refused (refusal rate of
9.4%) and 26 were excluded because of missing data
from their medical records. Thus, the final sample
comprised 223 patients.
Central obesity was defined as waist-to-hip ratio
greater than 0.95 for men and 0.85 for women.21 The
measurement of the waist-to-hip ratio has been vali-
dated for this sample of Brazilian HIV/AIDS patients
and has good correlation with visceral fat (r=0.74;
p=0.009) and total abdominal fat (r=0.82; p=0.002).4
Weight (kg) and height (m) were measured, and body
mass indexes (BMI, in kg/m2) were calculated accord-
ing to the World Health Organization (WHO) criteria
for classification.22 Peripheral subcutaneous fat was
evaluated by means of the subscapular and triceps
skinfolds (mm), taking the average of three measure-
ments made using Lange skinfold calipers, which
have a precision of 1.00 mm.
Current dietary intake was evaluated using two con-
secutive 24-hour dietary recall, excluding one week-
end day. Each participant was interviewed twice. A
nutritionist trained in the study protocol and using a
standardized procedure instructed participants on
how to describe their diet over the past 24-hour pe-
riod. Once data was collected, food intake registered
in the 24-hour dietary recall was converted into en-
ergy and nutrients by Virtual Nutri software* (ver-
sion 1.0; Department of Nutrition, Universidade de
São Paulo). The dietary variables studied were con-
sumption of energy (in kcal and kcal/kg), macro-
nutrients (in g and % of energy intake), total fiber,
and fruit and vegetables (g). Macronutrient intake in
grams (carbohydrates, proteins and lipids) was ad-
justed for total energy consumption using residual
nutrient method.20 In summary, this method allows to
assessing the net effect of nutrients without the influ-
ence of energy intake.
In addition to dietary recall, participants answered
two questionnaires. Questionnaire 1 collected data
on personal identification, demographic and socio-
economic factors and smoking habit. These variables
were self-reported information through the interview-
er’s guidance. Questionnaire 2 had to do with habitual
physical activity. It consisted of 16 questions as a
Likert scale and covered physical activity of the last
12 months by evaluating three components: occupa-
tional physical activity; physical exercise during lei-
sure time; and leisure and locomotion activities. Each
block of questions generated a final score for physi-
cal activity.5
The results from peripheral CD4+ T lymphocyte
counts for each patient, performed by means of flow
cytometry, were obtained from their respective medi-
cal records. Tests were performed no more than three
months prior to the patient’s admission to the present
study. Likewise, the history of the prescribed antiret-
roviral medication was obtained, and the total length
of protease inhibitor use (in months) was calculated.
Statistical analysis was performed using SPSS statis-
tical software (version 10.0). The association between
central obesity and demographic, clinical and anthro-
pometric variables was assessed using the Chi-square
test (categorical variables) and t-Student test (con-
tinuous variables).
A multiple logistic regression model was estimated
in order to evaluate the association between central
obesity and dietary intake, adjusting for potential
confounders, such as sex, age, skin color (black or
non-black), level of schooling (categories), income
(in reais - R$), BMI (kg/m2), physical activity (score),
smoking habits (yes/no), peripheral CD4+ T lymph-
ocyte count (categories) and length of protease inhib-
itor use. The dependent variable was central obesity
(yes/no) and dietary intake was the independent one.
For energy and macronutrients it was estimated the
change by 10 units and for the percentages of macro-
nutrients in calories it was estimated the change by 1
unit. All dietary intake variables were analyzed as a
continuous variable and a multiple model was esti-
mated for each one.
This study was approved by the Institutional Re-
view Board of the Faculdade de Saúde Pública and
Faculdade de Medicina of Universidade de São
Paulo, Brazil.
RESULTS
Of 223 individuals studied, the majority was male
(76.8%). The average age was 38.9 years, ranging from
20 to 59 years.
The prevalence of central obesity was 45.7% (95%
CI: 39.1-52.5%). The prevalence of underweight was
greater among women than men, 7.7% and 2.3% re-
spectively. Women also showed higher prevalence of
central obesity and overweight when compared to
men (Table 1).
Central obesity was greater among patients with less
schooling and those having better peripheral CD4+
T lymphocyte counts. The length of protease inhibi-
tor use was on average three months longer in the
*Virtual Nutrition software, version 1.0 [software em diskettes]. São Paulo: Departamento de Nutrição, Universidade de São Paulo; 1996.
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group with central obesity, but this difference was at
the limit of statistical significance (p=0.06). Other
selected characteristics are shown in Table 2.
The comparison of mean dietary intakes for patients
with and without central obesity is presented in Table
3. Patients with central obesity had mean carbohy-
drate intake significantly lower than those without
central obesity (53.6% vs 57.8%; p<0.01). The oppo-
site was observed for fat intake, which was greater
among those with central obesity (30.8 vs 27.7;
p<0.01). There were no significant differences in pro-
tein, total fiber, and fruit and vegetable intake. After
adjusting, energy for body weight (kcal/kg) intake was
significantly lower among patients with abnormal ab-
dominal fat redistribution (31.4 vs 35.3; p=0.04).
The results of the final logistic regression models for
dietary variables are shown in Table 4. The effect of
energy (kcal/kg) on the occurrence of abnormal fat
redistribution was lost after adjusting for sex, age,
skin color, schooling, income, BMI, physical activ-
ity, smoking habits and length of protease inhibitor
use. Carbohydrate consumption showed negative as-
sociation with central obesity. For every increase of
10 g of carbohydrates (value adjusted for energy),
the odds of central obesity decreased 0.93 times, that
is, 7%. On the other hand, a significant higher risk of
central obesity was observed with greater lipid in-
take. For every increase of 10 g of lipids the odds
increased 1.28 times. Considering the percent of en-
ergy intake, for every increase of 1 unit of lipids the
odds of central obesity increased 1.07 times, after
adjusting for control variables.
DISCUSSION
Redistribution of body fat has been increasingly rec-
ognized among HIV-infected individuals, and espe-
cially among those treated with protease inhibitors.1,2
In the present study, it was observed high prevalence
of central obesity, and it was significantly greater
among women than among men, and also among pa-
tients with less schooling. Previous studies6,14 on pa-
Table 1 - Population characteristics (means and percentages) according to nutritional status and sex. São Paulo, Brazil, 2002.
Male (n=171) Female (n=52) p-value
Characteristic n % 95% CI n % 95% CI
Waist-to-hip ratio*
Normal 99 57.9 50.1-65.4 22 42.3 28.7-56.9 0.048
Central obesity 72 42.1 34.6-49.9 30 57.7 43.2-71.3
Body mass index*
Underweight 4 2.3 0.6-5.9 4 7.7 2.1-18.5 0.063
Normal range 118 69.0 61.5-75.8 29 55.8 41.3-69.5
Pre-obese 43 25.1 18.8-32.3 14 26.9 15.6-41.0
Obese 6 3.5 1.3-7.5 5 9.6 3.2-21.0
*Waist-to-hip ratio classification: central obesity greater than 0.85 for women and 0.95 for men.22
**Body mass index classification: underweight (<18.5), normal range (18.5-24.9), overweight: pre-obese (25.0-29.9) and
obese (≥30.0).22
Table 2 - Population characteristics according to the presence of central obesity. São Paulo, Brazil, 2002.
Central obesity
Yes (n=102) No (n=121)
Characteristic n (%) n (%)
Skin color
Black 37 (44.0) 47 (56.0)
Non-black 65 (46.8) 74 (53.2)
Schooling*
Up to 8 years 37 (52.9) 33 (47.1)
9-12 years 37 (51.4) 35 (48.6)
13 years or over 27 (34.2) 52 (65.8)
CD4+ cell count (cell/mm3)**
≤200 20 (48.8) 21 (51.2)
201-349 35 (34.0) 68 (66.0)
≥350 47 (59.5) 32 (40.5)
Smoking habits
Yes 27 (39.7) 41 (60.3)
No 73 (48.4) 78 (51.6)
Mean; Standard deviation
Use of protease inhibitor (months) 34.1; 14.5 30.4;14.3
Age (years) 41.6; 7.4** 37.0; 6.9
Physical activity (score) 2.75; 0.70 2.88; 0.65
Body mass index (kg/m2) 25.6; 3.6** 22.2; 2.4
Waist circumference (cm) 93.1; 8.8** 80.6; 6.4
Hip circumference (cm) 95.0; 8.1** 91.2; 5.7
Waist-hip ratio 0.98; 0.1** 0.88; 0.1
Subscapular skinfold (mm) 25.5; 9.2* 17.6; 6.7
Triceps skinfold (mm) 9.8; 5.5 9.4; 4.7
*,**Statistically significant difference (Chi-square test for frequencies, Student’s t-test for means): *p<0.05; **p<0.001.
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tients treated with protease inhibitors have shown that
the accumulation of fat is frequently greater among
women and the development of android body patterns
characterized by increase adiposity in the trunk has
been reported among women with lipodystrophy.6,10
The authors believe that it was correct to define cases
of abdominal fat deposition by means of waist-hip
ratio. Waist circumference and waist-hip ratio increase
with the accumulation of visceral adiposity in indi-
viduals with or without HIV infection.4,12,21 Methods
were validated for estimating body fat of these HIV/
AIDS patients and visceral fat showed better correla-
tion with the measurement of waist-hip ratio (r=0.74;
p=0.009) than with the measurement of waist circum-
ference (r=0.60; p=0.050).4 It was observed that the
group of patients with central obesity presented sig-
nificantly greater mean BMI, which is an indicator of
total fat, and also significantly greater mean waist-
hip ratio, waist circumference and subscapular
skinfold, which are indicators of localized adiposity.
On the other hand, there was no significant differ-
ence in the triceps skinfold between the two groups.
This measurement is a parameter for evaluating lipo-
dystrophy due to fat atrophy.
The redistribution of body fat is known to be multifac-
torial.22 Exposure to protease inhibitors and, more re-
cently, to reverse transcriptase inhibitors has been im-
plicated in the etiology of this morphological abnor-
mality.2,7 It was observed that the length of protease
inhibitor use was longer among patients with fat redis-
tribution with a mean difference at the limit of statisti-
cal significance (p=0.06). In addition, it was noted that
central obesity occurred more frequently in individu-
als with better response to antiretroviral therapy, as
expressed by quantitative CD4+ T lymphocyte count,
which is consistent with other reports.11,12
The study findings suggest increased risk of central
obesity when there is lower carbohydrate intake
(OR=0.95) and greater lipid intake (OR=1.07), regard-
less of sex, age, skin color, schooling, income, BMI,
physical activity, smoking habits and length of pro-
tease inhibitor use. On the other hand, other studies
that have evaluated HIV-infected patients did not find
an association between the intake of these macro-
nutrients and fat deposition.1,9,11
Individuals without central obesity presented greater
mean energy intake per kg of body weight in the present
study. This difference was also observed in a case-con-
trol study by Hendricks et al11 for investigating the
development of abdominal fat deposition in HIV-posi-
Table 3 - Dietary intake of the population according to the presence of central obesity. São Paulo, Brazil, 2002.
Dietary variable Central obesity (mean ± SD) p-value**
Yes (n=102) No (n=121)
Energy (kcal) 2,225.4±915.9 2,242.0±891.0 0.89
Energy/weight (kcal/kg) 31.4±12.8 35.3±14.0 0.04
Percentage of calories (%)
Carbohydrates 53.6±10.6 57.8±10.0 <0.01
Proteins 16.1±4.3 15.4±5.3 0.32
Lipids 30.8±8.7 27.7±7.8 <0.01
Total carbohydrates (g)* 292.3±63.8 318.2±63.5 <0.01
Total proteins (g)* 88.8±24.8 85.9±32.6 0.46
Total lipids (g)* 80.1±22.9 70.8±22.4 <0.01
Total fiber (g)* 17.6±8.6 16.6±9.7 0.41
Total F&V (g) 236.0±202.2 259.3±262.9 0.48
*Nutrient intake adjusted for energy by using linear regression analysis
**Based on Student’s t-test for means
Table 4 - Association of dietary factors with the presence of central obesity. São Paulo, Brazil, 2002.
Dietary variables β
κ
ORaj** Change of odds
Per 1 unit
Energy (kcal) 0.000 1.00 (1.00; 1.00) -
Energy/weight (kcal/kg) 0.011 1.01 (0.98; 1.04) -
Percentage of calories (%)
Carbohydrates -0.050 0.95 (0.92; 0.98) -5%
Proteins 0.004 1.01 (0.94; 1.08) -
Lipids 0.071 1.07 (1.02; 1.12) +7%
Per 10 units
Total carbohydrates (g)* -0.007 0.93 (0.88; 0.98) -7%
Total proteins (g)* -0.001 0.99 (0.88; 1.11) -
Total lipids (g)* 0.025 1.28 (1.06; 1.56) +28%
Total fiber (g)* 0.004 1.04 (0.72; 1.51) -
Total F&V (g) -0.001 0.99 (0.97; 1.01) -
*Nutrient intake adjusted for energy by using linear regression analysis
**Logistic regression model with central obesity as exposure variable adjusted for sex, age, skin color, schooling, income,
body mass index, physical activity, smoking habits and length of protease inhibitor use (95% confidence interval between
parentheses)
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tive men. Since both body weight and BMI were sig-
nificantly greater in the group with central obesity, it
should be consider the possibility that there may have
been underreporting of energy intake, as well docu-
mented previously among overweight individuals.8,18
In contrast, greater total energy intake was observed
among patients with fat redistribution syndrome.1
For protein, total fiber, and fruit and vegetable intake it
was not find any differences in intake. A previous study
identified that fiber-rich diets are negatively associated
with fat deposition among HIV-infected individuals.11
In a study of the relationship between modifiable di-
etary habits, central obesity and metabolic abnormali-
ties, Hadigan et al9 observed that an increase of 5 g in
the daily intake of fiber was associated with a 14% re-
duction in the area under the glycemic curve (insulin
prediction area). However, there was no association with
fat redistribution pattern. Dietary factors such as fiber
intake may not be primary causes of morphological
abnormalities but may be indirectly related to such ab-
normalities by means of their association with meta-
bolic disturbances (hyperinsulinemia) that lead to the
accumulation of abdominal fat.
The present study had some limitations. As it was a cross-
sectional study focusing on abdominal fat deposition,
the results may not be applicable to other patterns of
morphological abnormalities resulting from the use of
protease inhibitors, such as fat atrophy. Nonetheless,
when the study results are added to previous studies,
they draw attention to the importance of healthy eating
habits in determining whether lipodystrophy will occur
or not. Moreover, it should be stressed that the use of
nutritional therapy for HIV-infected patients has re-
ceived little attention, even though many patients of-
ten express interest in this type of treatment.16,17
Ensuring good quality of life for HIV-infected indi-
viduals in the era of HAART is also associated to
preserving their corporal self-image, its physical as-
pects, and their self-esteem. Thus, the prevention of
morphological abnormalities has an important role,
not only from the point of view of reducing the meta-
bolic risk and risk of future chronic diseases, but also
for improving these patients’ quality of life.
To that aim, follow-up and nutritional intervention
studies are needed for evaluating the efficacy of nu-
tritional therapy for modifying the risks of morpho-
logical and metabolic abnormalities associated with
the use of antiretroviral therapy among HIV-infected
patients. Once the efficacy of this type of interven-
tion has been proven, it can be incorporated into the
set of integrated health care actions available for peo-
ple living with HIV/AIDS.
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